Determine the necessary mass, volume, or concentration for preparing a solution.
10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 ( PDE3 ) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research.
In Vitro
Vesnarinone (60 and 100 μg/mL; 48 h) inhibits the cell growth in a dose-dependent manner. Vesnarinone (60 μg/mL; 48 h) induces G1 arrest and apoptosis. Vesnarinone (60 μg/mL; 0, 12, 24, and 48 h) treatment increases p21-mRNA expression and decreases p21 protein slightly. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: OSC3, OSC4, and OSC5 cells Concentration: 60 μg/mL and 100 μg/mL Incubation Time: 48 hours Result: Observed more than 50% inhibition in cells treated with 100 μg/mL, and reduced 30±40% the production of MTT formazan in cells treated with 60 μg/mL. Apoptosis AnalysisCell Line: OSC3, OSC4, and OSC5 cells Concentration: 60 μg/mL Incubation Time: 48 hours Result: Decreased the tumor cell population in the S phase and increased in the G1 phase. Western Blot AnalysisCell Line: OSC3, OSC4, and OSC5 cells Concentration: 60 μg/mL Incubation Time: 0, 12, 24, and 48 hours Result: Increased the expression of p21-mRNA after 12±24 h vesnarinone treatment. Decreased p21 protein slightly after 24 h treatment in OSC4.
In Vivo
Vesnarinone (oral gavage; 300 mg/kg; once daily; 6 w) binds covalently to rat liver in vivo. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Lewis rats (200 g)Dosage: 300 mg/kg Administration: Oral gavage; 300 mg/kg; once daily; 6 weeks Result: Observed covalently modified liver proteins.
| Isomere SMILES | COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC |
|---|---|
| PubChem CID | 5663 |
| Molekulargewicht | 395.45 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →